Custom-Made vaccine targets aggressive brain tumors in early trial
NCT ID NCT04015700
First seen Feb 11, 2026 · Last updated Apr 29, 2026 · Updated 11 times
Summary
This early-phase study tests a personalized DNA vaccine for people with a fast-growing brain cancer called glioblastoma. The vaccine is custom-made for each patient based on their tumor's unique genetic changes. The goal is to see if the vaccine is safe and can train the immune system to fight the cancer. Only 9 patients with a specific type of glioblastoma (unmethylated MGMT) are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.